-transparent.png){kind=logo}
An iodinated cocaine derivative, N-(3'-iodopropen-2'-yl)-2 beta-carbomethoxy-3 beta-(4-chlorophenyl) tropane (IPT), was evaluated as a probe for in vitro and in vivo labeling of dopamine (DA) and serotonin (5-HT) transporters in Sprague-Dawley rat brain. Saturation analysis of [125I]IPT in rat striatal homogenates, in two different buffer solutions, Tris-HCl and phosphate, demonstrated a one-site binding with affinities (Kd) of 0.25 +/- 0.02 and 0.16 +/- 0.02 nM and densities (Bmax) of 939 +/- 161 and 1,982 +/- 137 fmol/mg protein, respectively. Competition by known DA transporter ligands showed a rank order of RTI-55 > IPT > GBR12909 > mazindol > (-)cocaine. Binding to 5-HT transporter sites was evaluated in rat cortical homogenates. Saturation experiment results showed a single site with a Kd value of 1.2 +/- 0.2 nM and a Bmax value of 100 +/- 20 fmol/mg protein. The rank order of potency of several monoamine uptake inhibitors (paroxetine > fluoxetine > mazindol > R-nisoxetine > GBR12909) suggests that [125I] IPT labels 5-HT transporters in rat cortical homogenates. Both ex vivo and in vitro autoradiographic studies revealed high densities of [125I]IPT binding sites in the caudate nucleus, putamen, olfactory tubercle and nucleus accumbens, areas known to be rich in dopaminergic innervation. Moderate accumulation of activity was also observed in the substantia nigra. The dorsal raphe, a region with a high density of 5-HT innervation, was labeled using in vitro autoradiography with [125I]IPT, but the labeling using ex vivo autoradiography was less prominent at 30 min postinjection and not noticeable at 60 min postinjection.(ABSTRACT TRUNCATED AT 250 WORDS)
M P Kung, and
W D Essman, and
D Frederick, and
S Meegalla, and
M Goodman, and
M Mu, and
I Lucki, and
H F Kung
November 1987,
FEBS letters,
M P Kung, and
W D Essman, and
D Frederick, and
S Meegalla, and
M Goodman, and
M Mu, and
I Lucki, and
H F Kung
June 2009,
Bioorganic & medicinal chemistry,
M P Kung, and
W D Essman, and
D Frederick, and
S Meegalla, and
M Goodman, and
M Mu, and
I Lucki, and
H F Kung
January 1997,
Life sciences,
M P Kung, and
W D Essman, and
D Frederick, and
S Meegalla, and
M Goodman, and
M Mu, and
I Lucki, and
H F Kung
July 1985,
European journal of pharmacology,
M P Kung, and
W D Essman, and
D Frederick, and
S Meegalla, and
M Goodman, and
M Mu, and
I Lucki, and
H F Kung
October 2002,
The Journal of pharmacology and experimental therapeutics,
M P Kung, and
W D Essman, and
D Frederick, and
S Meegalla, and
M Goodman, and
M Mu, and
I Lucki, and
H F Kung
December 1995,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
M P Kung, and
W D Essman, and
D Frederick, and
S Meegalla, and
M Goodman, and
M Mu, and
I Lucki, and
H F Kung
October 1989,
Molecular pharmacology,
M P Kung, and
W D Essman, and
D Frederick, and
S Meegalla, and
M Goodman, and
M Mu, and
I Lucki, and
H F Kung
January 1998,
Life sciences,
M P Kung, and
W D Essman, and
D Frederick, and
S Meegalla, and
M Goodman, and
M Mu, and
I Lucki, and
H F Kung
January 1991,
Psychopharmacology,
M P Kung, and
W D Essman, and
D Frederick, and
S Meegalla, and
M Goodman, and
M Mu, and
I Lucki, and
H F Kung
April 2005,
Journal of neuroscience methods,
